MX2009004426A - Derivados biciclicos fusionados de 2,4-diaminopirimidina como inhibidores alk y c-met. - Google Patents
Derivados biciclicos fusionados de 2,4-diaminopirimidina como inhibidores alk y c-met.Info
- Publication number
- MX2009004426A MX2009004426A MX2009004426A MX2009004426A MX2009004426A MX 2009004426 A MX2009004426 A MX 2009004426A MX 2009004426 A MX2009004426 A MX 2009004426A MX 2009004426 A MX2009004426 A MX 2009004426A MX 2009004426 A MX2009004426 A MX 2009004426A
- Authority
- MX
- Mexico
- Prior art keywords
- alk
- diaminopyrimidine
- fused bicyclic
- met inhibitors
- bicyclic derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
La presente invención proporciona un compuest.o de la fórmula I ó II (ver fórmulas) o una sal farmacéuticamente aceptable del mismo, en donde R1, R2, R3, R4, R5, A1, A2, A3, A4, y A5, son como se define en la presente. Los compuestos de la fórmula I ó II tienen actividad inhibidora ALK y/o c-Met, y se pueden usar para tratar trastornos proliferativos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85356206P | 2006-10-23 | 2006-10-23 | |
PCT/US2007/022496 WO2008051547A1 (en) | 2006-10-23 | 2007-10-23 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009004426A true MX2009004426A (es) | 2009-08-12 |
Family
ID=39050187
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009004426A MX2009004426A (es) | 2006-10-23 | 2007-10-23 | Derivados biciclicos fusionados de 2,4-diaminopirimidina como inhibidores alk y c-met. |
Country Status (15)
Country | Link |
---|---|
US (2) | US8148391B2 (es) |
EP (2) | EP2222647B1 (es) |
JP (1) | JP5512274B2 (es) |
CN (1) | CN101535276B (es) |
AR (1) | AR063527A1 (es) |
AU (1) | AU2007309427B2 (es) |
CA (1) | CA2669111C (es) |
CL (1) | CL2007003049A1 (es) |
ES (2) | ES2555803T3 (es) |
HK (1) | HK1147748A1 (es) |
IL (1) | IL198150A (es) |
MX (1) | MX2009004426A (es) |
NZ (1) | NZ576425A (es) |
TW (1) | TWI432427B (es) |
WO (1) | WO2008051547A1 (es) |
Families Citing this family (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
US8710045B2 (en) * | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
MX2009004426A (es) * | 2006-10-23 | 2009-08-12 | Cephalon Inc | Derivados biciclicos fusionados de 2,4-diaminopirimidina como inhibidores alk y c-met. |
UA100846C2 (uk) | 2006-12-08 | 2013-02-11 | Айерем Елелсі | Сполуки та композиція як інгібітори протеїнкінази |
CA2671744C (en) * | 2006-12-08 | 2012-08-28 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
CA2681015C (en) | 2007-03-16 | 2016-06-21 | The Scripps Research Institute | Inhibitors of focal adhesion kinase |
TWI389893B (zh) | 2007-07-06 | 2013-03-21 | Astellas Pharma Inc | 二(芳胺基)芳基化合物 |
BRPI0815979A2 (pt) | 2007-08-28 | 2017-06-13 | Irm Llc | compostos e composições com inibidores de quinase, bem como uso dos mesmos |
US20100056524A1 (en) * | 2008-04-02 | 2010-03-04 | Mciver Edward Giles | Compound |
US8592432B2 (en) | 2008-04-07 | 2013-11-26 | Bei Chen | Compounds and compositions as protein kinase inhibitors |
WO2009127642A2 (en) * | 2008-04-15 | 2009-10-22 | Cellzome Limited | Use of lrrk2 inhibitors for neurodegenerative diseases |
US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
AU2009244897B2 (en) | 2008-04-16 | 2014-11-13 | Alexion Pharmaceuticals, Inc. | 2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or JAK kinases inhibitors |
HUE035029T2 (en) | 2008-05-21 | 2018-03-28 | Ariad Pharma Inc | Kinase inhibitor phosphorus derivatives |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
UY31929A (es) | 2008-06-25 | 2010-01-05 | Irm Llc | Compuestos y composiciones como inhibidores de cinasa |
US8445505B2 (en) | 2008-06-25 | 2013-05-21 | Irm Llc | Pyrimidine derivatives as kinase inhibitors |
PL2889033T3 (pl) | 2008-11-19 | 2018-10-31 | Forum Pharmaceuticals Inc. | Leczenie negatywnych objawów schizofrenii za pomocą (R)-7-chloro-N-(chinuklidyn-3-ylo)benzo[b]tiofeno-2-karboksyamidu i jego farmaceutycznie dopuszczalnych soli |
AU2009322393B2 (en) | 2008-12-03 | 2017-02-02 | Presidio Pharmaceuticals, Inc. | Inhibitors of HCV NS5A |
US20110071158A1 (en) * | 2009-03-18 | 2011-03-24 | Boehringer Ingelheim International Gmbh | New compounds |
PL2428508T3 (pl) | 2009-05-08 | 2016-05-31 | Astellas Pharma Inc | Diaminoheterocykliczny związek karboksyamidowy |
WO2010132423A1 (en) * | 2009-05-11 | 2010-11-18 | Envivo Pharmaceuticals, Inc. | Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors |
TW201100441A (en) | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
EP2440534A2 (en) * | 2009-06-10 | 2012-04-18 | Cellzome Limited | Pyrimidine derivatives as zap-70 inhibitors |
KR101351120B1 (ko) * | 2009-06-10 | 2014-01-15 | 추가이 세이야쿠 가부시키가이샤 | 4환성 화합물 |
ES2642586T3 (es) * | 2009-07-27 | 2017-11-16 | Gilead Sciences, Inc. | Compuestos heterocíclicos condensados como moduladores de canales iónicos |
US8933227B2 (en) | 2009-08-14 | 2015-01-13 | Boehringer Ingelheim International Gmbh | Selective synthesis of functionalized pyrimidines |
WO2011018517A1 (en) | 2009-08-14 | 2011-02-17 | Boehringer Ingelheim International Gmbh | Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives |
CA2779088A1 (en) * | 2009-11-16 | 2011-05-19 | Mellitech | [1,5]-diazocin derivatives |
MX2012013345A (es) | 2010-05-17 | 2013-02-11 | Envivo Pharmaceuticals Inc | Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin- 3-il)benzo[b]tiofeno-2-carboxamida monohidratado. |
EP2588107A1 (en) | 2010-07-01 | 2013-05-08 | Takeda Pharmaceutical Company Limited | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET |
BR112012033402A2 (pt) | 2010-07-02 | 2017-01-24 | Gilead Sciences Inc | moduladores de canais de íons conforme os compostos heterocíclicos fundidos |
US20120101108A1 (en) | 2010-08-06 | 2012-04-26 | Cell Signaling Technology, Inc. | Anaplastic Lymphoma Kinase In Kidney Cancer |
KR101362589B1 (ko) * | 2010-08-20 | 2014-02-12 | 추가이 세이야쿠 가부시키가이샤 | 4환성 화합물을 포함하는 조성물 |
JP5006987B2 (ja) * | 2010-11-22 | 2012-08-22 | 中外製薬株式会社 | 4環性化合物を含む医薬 |
WO2012074951A1 (en) | 2010-11-29 | 2012-06-07 | OSI Pharmaceuticals, LLC | Macrocyclic kinase inhibitors |
CN103501612B (zh) | 2011-05-04 | 2017-03-29 | 阿里亚德医药股份有限公司 | 抑制表皮生长因子受体导致的癌症中细胞增殖的化合物 |
EA028156B9 (ru) | 2011-05-10 | 2018-01-31 | Джилид Сайэнс, Инк. | Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов |
NO3175985T3 (es) | 2011-07-01 | 2018-04-28 | ||
TWI549944B (zh) | 2011-07-01 | 2016-09-21 | 吉李德科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
EP2554544A1 (en) * | 2011-08-01 | 2013-02-06 | Almirall, S.A. | Pyridin-2(1h)-one derivatives as jak inhibitors |
SG10201601352UA (en) | 2011-11-23 | 2016-03-30 | Portola Pharm Inc | Pyrazine kinase inhibitors |
KR102012057B1 (ko) * | 2011-11-29 | 2019-08-19 | 제넨테크, 인크. | Lrrk2 조절제로서 아미노피리미딘 유도체 |
HUE027976T2 (en) * | 2012-03-06 | 2016-11-28 | Cephalon Inc | Condensed ring bicyclic 2,4-diaminopyrimidine derivative as dual ALK and FAK inhibitor |
AU2013204563B2 (en) | 2012-05-05 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
CA2872005A1 (en) | 2012-05-08 | 2013-11-14 | Forum Pharmaceuticals, Inc. | Methods of maintaining, treating or improving cognitive function |
KR101446742B1 (ko) | 2012-08-10 | 2014-10-01 | 한국화학연구원 | N2,n4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
CN103664903A (zh) * | 2012-09-04 | 2014-03-26 | 中国科学院上海药物研究所 | 苯氮卓类化合物及其制备方法和用途 |
US10668075B2 (en) | 2012-09-25 | 2020-06-02 | Chugai Seiyaku Kabushiki Kaisha | RET inhibitor |
AU2013344049B2 (en) * | 2012-11-06 | 2017-12-21 | Fochon Pharmaceuticals, Ltd. | ALK kinase inhibitors |
CN104968667B (zh) * | 2013-02-05 | 2017-06-20 | 山东轩竹医药科技有限公司 | 四并环激酶抑制剂 |
JP2016509045A (ja) | 2013-02-22 | 2016-03-24 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | がんを治療し、薬剤耐性を防止する方法 |
EP2970205B1 (en) | 2013-03-14 | 2019-05-08 | Tolero Pharmaceuticals, Inc. | Jak2 and alk2 inhibitors and methods for their use |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
KR20160020502A (ko) | 2013-06-18 | 2016-02-23 | 노파르티스 아게 | 제약 조합물 |
WO2015038868A1 (en) * | 2013-09-13 | 2015-03-19 | Cephalon, Inc. | Fused bicyclic 2,4-diaminopyrimidine derivatives |
KR101656382B1 (ko) | 2014-02-28 | 2016-09-09 | 한국화학연구원 | 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물 |
AR100187A1 (es) | 2014-04-25 | 2016-09-14 | Chugai Pharmaceutical Co Ltd | Composición farmacéutica que contiene un inhibidor de alk (quinasa de linfoma anaplásico) |
KR20220042486A (ko) | 2014-04-25 | 2022-04-05 | 추가이 세이야쿠 가부시키가이샤 | 4환성 화합물의 신규 결정 |
EP3140298A1 (en) | 2014-05-07 | 2017-03-15 | Pfizer Inc. | Tropomyosin-related kinase inhibitors |
EP3150592B1 (en) * | 2014-05-30 | 2023-08-30 | Shanghai Emerald Wellcares Pharmaceutical Co., LTD | Alk kinase inhibitor, and preparation method and use thereof |
CA2952787A1 (en) * | 2014-06-17 | 2015-12-23 | Korea Research Institute Of Chemical Technology | Pyrimidine-2,4-diamine derivative and anticancer pharmaceutical composition comprising same as effective ingredient |
TWI765410B (zh) | 2014-08-08 | 2022-05-21 | 日商中外製藥股份有限公司 | 4環性化合物的非晶質體的用途 |
KR101633722B1 (ko) | 2014-10-08 | 2016-06-28 | 한국화학연구원 | 4-(1-퍼롤-3,4-디카르복시아미드)피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
CN105524045B (zh) * | 2014-10-22 | 2020-04-10 | 山东轩竹医药科技有限公司 | 四环类间变性淋巴瘤激酶抑制剂 |
WO2016087370A1 (en) * | 2014-12-01 | 2016-06-09 | Actelion Pharmaceuticals Ltd | Cxcr7 receptor modulators |
US10398774B2 (en) | 2014-12-09 | 2019-09-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Human monoclonal antibodies against AXL |
WO2016100711A1 (en) * | 2014-12-18 | 2016-06-23 | The Broad Institute, Inc. | Modulators of hepatic lipoprotein metabolism |
BR112017013982A2 (pt) | 2015-01-16 | 2018-01-02 | Chugai Seiyaku Kabushiki Kaisha | fármaco de combinação |
WO2016135041A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
KR101772134B1 (ko) | 2015-04-14 | 2017-08-29 | 한국화학연구원 | N2-(2-메톡시페닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
KR101653571B1 (ko) | 2015-04-22 | 2016-09-05 | 한국화학연구원 | 4-(2-아미노-테트라하이드로나프탈렌닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
CN105400143B (zh) * | 2015-12-11 | 2017-10-03 | 广州欣凯化工科技有限公司 | 一种木制品缝隙的修补组合物 |
AU2017208119B2 (en) | 2016-01-15 | 2019-11-07 | Pfizer Inc. | 6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands |
KR20190013553A (ko) | 2017-07-28 | 2019-02-11 | 주식회사유한양행 | 아미노피리미딘 유도체의 개선된 제조방법 |
CN111032630B (zh) * | 2017-08-18 | 2022-12-16 | 北京韩美药品有限公司 | 一种化合物,其药物组合物及其用途及应用 |
CN110240545B (zh) * | 2018-03-08 | 2022-04-26 | 迈克斯(如东)化工有限公司 | 一种2-(5-氟-2,4-二硝基苯氧)乙酸的制备方法 |
TWI674931B (zh) * | 2018-03-13 | 2019-10-21 | 川尚股份有限公司 | 污染混合物的處理方法 |
JP7149089B2 (ja) * | 2018-03-26 | 2022-10-06 | 株式会社日本触媒 | 含窒素複素環化合物およびスクアリリウム化合物の製造方法 |
MX2021000977A (es) | 2018-07-26 | 2021-04-12 | Sumitomo Pharma Oncology Inc | Metodos para tratar enfermedades asociadas con expresion anormal de receptor de activina a tipo 1 (acvr1) e inhibidores de acvr1 para uso en los mismos. |
JP7167171B2 (ja) | 2018-09-04 | 2022-11-08 | 中外製薬株式会社 | 4環性化合物の製造方法 |
CN109632773B (zh) * | 2019-01-08 | 2021-11-12 | 贵州大学 | 一种二氢硫辛酸琥珀酰转移酶抑制剂的筛选方法 |
MX2022000164A (es) | 2019-07-03 | 2022-04-01 | Sumitomo Pharma Oncology Inc | Inhibidores de tirosina cinasa no receptora 1 (tnk1) y usos de los mismos. |
AU2020372382B2 (en) * | 2019-10-22 | 2023-09-14 | Alphala Co., Ltd. | Pyrimidine amide compounds and use thereof |
CN110950797A (zh) * | 2019-12-06 | 2020-04-03 | 丽水绿氟科技有限公司 | 一种2-三氟甲基-3-氟-4-吡啶甲酸及其衍生物的制备方法 |
AU2021227907A1 (en) * | 2020-02-25 | 2022-09-29 | Dana-Farber Cancer Institute, Inc. | Potent and selective degraders of ALK |
KR20230002721A (ko) * | 2020-04-14 | 2023-01-05 | 치루 파머수티컬 컴퍼니 리미티드 | Egfr 억제제로서의 삼환계 화합물 |
CN115697993A (zh) * | 2020-05-29 | 2023-02-03 | 南京正大天晴制药有限公司 | 作为axl抑制剂的嘧啶类化合物 |
CN112213428A (zh) * | 2020-10-13 | 2021-01-12 | 辽宁科技大学 | 一种超临界co2中进行非催化乙酰基化反应及其在线检测方法 |
AU2022205713A1 (en) * | 2021-01-07 | 2023-07-27 | Ontario Institute For Cancer Research (Oicr) | Thienyl and cycloalkyl aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof |
TW202246263A (zh) * | 2021-03-23 | 2022-12-01 | 大陸商杭州阿諾生物醫藥科技有限公司 | Hpk1激酶抑制劑化合物 |
EP4320153A1 (en) | 2021-04-09 | 2024-02-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of anaplastic large cell lymphoma |
CN115838383A (zh) * | 2021-09-22 | 2023-03-24 | 南京正大天晴制药有限公司 | 作为axl抑制剂的苯并环庚烷类化合物 |
TW202317117A (zh) * | 2021-10-14 | 2023-05-01 | 大陸商齊魯製藥有限公司 | 一種三環化合物的用途 |
CN114133360A (zh) * | 2021-11-30 | 2022-03-04 | 南京工业大学 | 一种含氟苯并[d]-1,3-氧氮杂卓化合物及其合成方法 |
CN114539104A (zh) * | 2022-03-09 | 2022-05-27 | 常州佳德医药科技有限公司 | 一种艾拉莫德中间体的制备方法 |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2297910A1 (en) | 1997-07-25 | 1999-02-04 | Smithkline Beecham Corporation | Vitronectin receptor antagonist |
HU230522B1 (hu) * | 1998-03-27 | 2016-10-28 | Janssen Pharmaceutica N.V | HIV-gátló pirimidinszármazékok |
GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
GB9914258D0 (en) | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
US6906067B2 (en) | 1999-12-28 | 2005-06-14 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of TNF-α expression |
GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
MXPA03010810A (es) | 2001-05-29 | 2004-03-22 | Schering Ag | Pirimidinas inhibidoras de cdk, su obtencion y su uso como medicamentos. |
WO2003002544A1 (en) | 2001-06-26 | 2003-01-09 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of tnf-alpha expression |
US7115617B2 (en) | 2001-08-22 | 2006-10-03 | Amgen Inc. | Amino-substituted pyrimidinyl derivatives and methods of use |
US6939874B2 (en) | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
WO2003026664A1 (en) | 2001-09-26 | 2003-04-03 | Bayer Corporation | 2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors |
WO2003032997A1 (de) * | 2001-10-17 | 2003-04-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung |
EP1453516A2 (de) | 2001-10-17 | 2004-09-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren |
DK1442024T3 (da) | 2001-11-01 | 2008-06-30 | Janssen Pharmaceutica Nv | Aminobenzamidderivater som glycogensystasekinase 3 beta-inhibitorer |
US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
WO2003055489A1 (en) | 2001-12-21 | 2003-07-10 | Bayer Pharmaceuticals Corporation | 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
TWI329105B (en) * | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
ATE466580T1 (de) | 2002-03-15 | 2010-05-15 | Vertex Pharma | Azolylaminoazine als proteinkinasehemmer |
GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
EP1485381B8 (en) | 2002-03-15 | 2010-05-12 | Vertex Pharmaceuticals Incorporated | Azolylaminoazine as inhibitors of protein kinases |
AU2003218215A1 (en) | 2002-03-15 | 2003-09-29 | Vertex Pharmaceuticals, Inc. | Azolylaminoazines as inhibitors of protein kinases |
WO2003095448A1 (en) | 2002-05-06 | 2003-11-20 | Bayer Pharmaceuticals Corporation | Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders |
WO2004002964A1 (ja) * | 2002-06-28 | 2004-01-08 | Yamanouchi Pharmaceutical Co., Ltd. | ジアミノピリミジンカルボキサミド誘導体 |
IL166241A0 (en) | 2002-07-29 | 2006-01-15 | Rigel Pharmaceuticals Inc | Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds |
PL216368B1 (pl) | 2003-02-26 | 2014-03-31 | Sugen | Związki aminoheteroarylowe oraz ich zastosowanie |
GB0305929D0 (en) * | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
US7504396B2 (en) | 2003-06-24 | 2009-03-17 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
US7037909B2 (en) | 2003-07-02 | 2006-05-02 | Sugen, Inc. | Tetracyclic compounds as c-Met inhibitors |
US20060009493A1 (en) | 2003-07-02 | 2006-01-12 | Sugen, Inc. | Indolinone hydrazides as c-Met inhibitors |
US7122548B2 (en) | 2003-07-02 | 2006-10-17 | Sugen, Inc. | Triazolotriazine compounds and uses thereof |
WO2005006945A2 (en) | 2003-07-03 | 2005-01-27 | The Salk Institute For Biological Studies | Methods for treating neural disorders and compounds useful therefor |
CA2532800C (en) | 2003-07-23 | 2013-06-18 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
US7442698B2 (en) | 2003-07-24 | 2008-10-28 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
DK1656372T3 (da) | 2003-07-30 | 2013-07-01 | Rigel Pharmaceuticals Inc | 2,4-pyrimidindiaminforbindelser til anvendelse til behandling eller forebyggelse af autoimmunsygdomme |
ES2365223T3 (es) | 2003-08-07 | 2011-09-26 | Rigel Pharmaceuticals, Inc. | Compuestos 2,4-pirimidindiamínicos y usos como agentes antiproliferativos. |
MXPA06001759A (es) * | 2003-08-15 | 2006-05-12 | Novartis Ag | 2,4-pirimidinadiaminas utiles en el tratamiento de enfermedades neoplasticas, desordenes del sistema inmune e inflamatorios. |
TWI339206B (en) | 2003-09-04 | 2011-03-21 | Vertex Pharma | Compositions useful as inhibitors of protein kinases |
GB0321710D0 (en) * | 2003-09-16 | 2003-10-15 | Novartis Ag | Organic compounds |
CA2538413A1 (en) * | 2003-09-18 | 2005-03-24 | Novartis Ag | 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders |
EP2213661B1 (en) | 2003-09-26 | 2011-07-20 | Exelixis Inc. | c-Met Modulators and Methods of Use |
US7144889B2 (en) | 2003-10-16 | 2006-12-05 | Hoffman-La Roche Inc. | Triarylimidazoles |
US7169781B2 (en) | 2003-10-17 | 2007-01-30 | Hoffmann-La Roche Inc. | Imidazole derivatives and their use as pharmaceutical agents |
EP1694652A1 (en) | 2003-12-19 | 2006-08-30 | Rigel Pharmaceuticals, Inc. | Stereoisomers and stereoisomeric mixtures of 1-(2,4-pyrimidinediamino)-2-cyclopentanecarboxamide synthetic intermediates |
TW200536851A (en) | 2004-01-23 | 2005-11-16 | Amgen Inc | Compounds and methods of use |
WO2005080393A1 (en) | 2004-02-14 | 2005-09-01 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
BRPI0507834A (pt) | 2004-02-23 | 2007-07-10 | Sugen Inc | método para tratar o crescimento celular anormal usando inibidores de c-met e de m-tor |
EP1730128A1 (en) | 2004-03-31 | 2006-12-13 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
TW200538453A (en) | 2004-04-26 | 2005-12-01 | Bristol Myers Squibb Co | Bicyclic heterocycles as kinase inhibitors |
MXPA06013165A (es) | 2004-05-14 | 2007-02-13 | Pfizer Prod Inc | Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal. |
EP1751142A1 (en) | 2004-05-14 | 2007-02-14 | Pfizer Products Incorporated | Pyrimidines derivatives for the treatment of abnormal cell growth |
EP1763514A2 (en) | 2004-05-18 | 2007-03-21 | Rigel Pharmaceuticals, Inc. | Cycloalkyl substituted pyrimidinediamine compounds and their uses |
EP1598343A1 (de) | 2004-05-19 | 2005-11-23 | Boehringer Ingelheim International GmbH | 2-Arylaminopyrimidine als PLK Inhibitoren |
US7521457B2 (en) | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
GB0419161D0 (en) | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
GB0419160D0 (en) * | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
GB2420559B (en) | 2004-11-15 | 2008-08-06 | Rigel Pharmaceuticals Inc | Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses |
US8211929B2 (en) | 2004-12-30 | 2012-07-03 | Exelixis, Inc. | Pyrimidine derivatives as kinase modulators and method of use |
WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
KR101312225B1 (ko) | 2005-06-08 | 2013-09-26 | 리겔 파마슈티칼스, 인크. | Jak 경로의 억제를 위한 조성물 및 방법 |
US20070032514A1 (en) | 2005-07-01 | 2007-02-08 | Zahn Stephan K | 2,4-diamino-pyrimidines as aurora inhibitors |
MX2008000574A (es) | 2005-07-11 | 2008-03-14 | Sanofi Aventis | Nuevos derivados de 2,4-dianilinopirimidinas, la preparacion de los mismos, su uso como medicamentos, composiciones farmaceuticas y, en particular, como inhibidores ikk. |
WO2007028445A1 (en) | 2005-07-15 | 2007-03-15 | Glaxo Group Limited | 6-indolyl-4-yl-amino-5-halogeno-2-pyrimidinyl-amino derivatives |
KR100674813B1 (ko) | 2005-08-05 | 2007-01-29 | 일양약품주식회사 | N-페닐-2-피리미딘-아민 유도체 및 그의 제조방법 |
JP5191391B2 (ja) | 2005-11-01 | 2013-05-08 | ターゲジェン インコーポレーティッド | キナーゼのビ−アリールメタ−ピリミジン阻害剤 |
UA89123C2 (ru) * | 2005-12-21 | 2009-12-25 | Пфайзер Продактс Инк. | Производные пиримидина для лечения абнормального роста клеток |
TW200736232A (en) | 2006-01-26 | 2007-10-01 | Astrazeneca Ab | Pyrimidine derivatives |
KR20080110998A (ko) | 2006-01-30 | 2008-12-22 | 엑셀리시스, 인코포레이티드 | Jak2 조절자로서 4아릴2아미노피리미딘 또는 4아릴2아미노알킬피리미딘 및 이들을 포함하는 약제학적 조성물 |
TW200804364A (en) | 2006-02-22 | 2008-01-16 | Boehringer Ingelheim Int | New compounds |
WO2008003766A2 (en) | 2006-07-06 | 2008-01-10 | Boehringer Ingelheim International Gmbh | 4-heter0cycl0alkylpyri(mi)dines, process for the preparation thereof and their use as medicaments |
MX2009004426A (es) * | 2006-10-23 | 2009-08-12 | Cephalon Inc | Derivados biciclicos fusionados de 2,4-diaminopirimidina como inhibidores alk y c-met. |
UA100846C2 (uk) | 2006-12-08 | 2013-02-11 | Айерем Елелсі | Сполуки та композиція як інгібітори протеїнкінази |
CA2671744C (en) | 2006-12-08 | 2012-08-28 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
-
2007
- 2007-10-23 MX MX2009004426A patent/MX2009004426A/es active IP Right Grant
- 2007-10-23 TW TW096139772A patent/TWI432427B/zh not_active IP Right Cessation
- 2007-10-23 US US12/162,851 patent/US8148391B2/en active Active
- 2007-10-23 ES ES07861484.9T patent/ES2555803T3/es active Active
- 2007-10-23 AR ARP070104687A patent/AR063527A1/es not_active Application Discontinuation
- 2007-10-23 EP EP07861484.9A patent/EP2222647B1/en active Active
- 2007-10-23 CL CL200703049A patent/CL2007003049A1/es unknown
- 2007-10-23 NZ NZ576425A patent/NZ576425A/xx unknown
- 2007-10-23 CA CA2669111A patent/CA2669111C/en active Active
- 2007-10-23 CN CN2007800394641A patent/CN101535276B/zh active Active
- 2007-10-23 AU AU2007309427A patent/AU2007309427B2/en active Active
- 2007-10-23 WO PCT/US2007/022496 patent/WO2008051547A1/en active Application Filing
- 2007-10-23 JP JP2009534629A patent/JP5512274B2/ja active Active
- 2007-10-23 EP EP13173365.1A patent/EP2684874B1/en active Active
- 2007-10-23 ES ES13173365.1T patent/ES2633318T3/es active Active
-
2009
- 2009-04-16 IL IL198150A patent/IL198150A/en active IP Right Grant
-
2011
- 2011-02-24 HK HK11101845.2A patent/HK1147748A1/xx unknown
-
2012
- 2012-03-06 US US13/413,322 patent/US8552186B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
IL198150A0 (en) | 2009-12-24 |
AU2007309427A1 (en) | 2008-05-02 |
CA2669111A1 (en) | 2008-05-02 |
EP2684874B1 (en) | 2017-05-17 |
CN101535276B (zh) | 2013-08-28 |
CN101535276A (zh) | 2009-09-16 |
CL2007003049A1 (es) | 2008-05-16 |
EP2684874A1 (en) | 2014-01-15 |
JP5512274B2 (ja) | 2014-06-04 |
US20120165519A1 (en) | 2012-06-28 |
US20090221555A1 (en) | 2009-09-03 |
EP2222647B1 (en) | 2015-08-05 |
IL198150A (en) | 2014-06-30 |
US8148391B2 (en) | 2012-04-03 |
US8552186B2 (en) | 2013-10-08 |
NZ576425A (en) | 2012-04-27 |
TWI432427B (zh) | 2014-04-01 |
CA2669111C (en) | 2016-04-12 |
HK1147748A1 (en) | 2011-08-19 |
ES2555803T3 (es) | 2016-01-08 |
WO2008051547A1 (en) | 2008-05-02 |
AU2007309427B2 (en) | 2013-02-28 |
EP2222647A1 (en) | 2010-09-01 |
ES2633318T3 (es) | 2017-09-20 |
JP2010507665A (ja) | 2010-03-11 |
AR063527A1 (es) | 2009-01-28 |
TW200833686A (en) | 2008-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200833686A (en) | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors | |
MY147390A (en) | Substituted isoindoles as bace inhibitors and their use | |
TW200612936A (en) | Indole derivatives | |
IL189191A0 (en) | Thiazolyl piperidine derivatives useful as h3 receptor modulators | |
TW200718692A (en) | Dihydrobenzofuran derivatives and uses thereof | |
NZ591166A (en) | Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) | |
MX2009012168A (es) | Derivados de pirrolopiridina y su uso como inhibidores de la enzima que escinde la proteina precursora de amiloide por el sitio beta. | |
MX2010001486A (es) | Derivados de tetrahidropiridin carboxamida como antagonistas de trpvl. | |
WO2007062999A3 (en) | 1,5-substituted indol-2-yl amide derivatives | |
MX2009012595A (es) | Derivados de espiroindolinona. | |
MX2009003316A (es) | Derivados de pirazina-2-carboxamida como moduladores receptores de cb2. | |
TW200736233A (en) | Cyclohexyl piperazinyl methanone derivatives | |
MX2010002760A (es) | Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina-3. | |
WO2007108936A3 (en) | N-substituted-azacyclylamines as histamine-3 antagonists | |
WO2007142905A3 (en) | 1-sulfonylindazolylamine and -amide derivatives as 5-hydroxytryptamine-6 ligands | |
MX2007006387A (es) | Derivados de piridina 3-substituidos como antagonistas h3. | |
ATE449776T1 (de) | Pyrroloä2,3-cüpyridinderivate | |
MX2010002899A (es) | Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de la histamina-3. | |
TW200637817A (en) | 5-aminoindole derivatives | |
TW200738651A (en) | Cyclohexyl sulfonamide derivatives | |
WO2007136668A3 (en) | N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists | |
MX2009011059A (es) | Aminopirimidinas utiles como inhibidores de cinasas. | |
GB0513886D0 (en) | Novel compounds | |
WO2008131946A3 (de) | Substituierte amid-derivate | |
IL194057A0 (en) | Pyrimidine, quinazoline, pteridine and triazine derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |